These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8080316)

  • 41. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Case management of the anemic patient: epoetin alfa--focus on iron supplementation.
    Kirlin LF
    ANNA J; 1993 Dec; 20(6):678-81. PubMed ID: 8267412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Administering epoetin alfa. More RBCs with fewer risks.
    Biggers PB
    Nursing; 1991 Apr; 21(4):43. PubMed ID: 2020418
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Jones M; Ibels L; Schenkel B; Zagari M
    Kidney Int; 2004 Mar; 65(3):757-67. PubMed ID: 14871396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant human erythropoietin in predialysis patients.
    Lim VS
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):34-7. PubMed ID: 1928077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epoetin alfa--focus on the geriatric patient. Case study of the anemic patient.
    Mathers T
    ANNA J; 1995 Oct; 22(5):494-7. PubMed ID: 7487195
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Case study of the anemic patient: epoetin alfa--focus on iron management.
    Kirlin LF
    ANNA J; 1995 Apr; 22(2):192-5. PubMed ID: 7786067
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The use of epoetin beta in anemic predialysis patients with chronic renal failure.
    Koch KM; Koene RA; Messinger D; Quarder O; Scigalla P
    Clin Nephrol; 1995 Sep; 44(3):201-8. PubMed ID: 8556837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case study of the anemic patient: epoetin alfa--focus on sexual function.
    Zarifian A
    ANNA J; 1994 Oct; 21(6):368-71. PubMed ID: 7993143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erythropoietin therapy in patients with chronic renal failure.
    Pinevich AJ; Petersen J
    West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epoetin alfa: a keystone in the treatment of the anemic patient with chronic renal failure. Proceedings of a symposium held April 27, 1989, by the Keystone Chapter of ANNA, Valley Forge, Pennsylvania.
    Binkley L; Gallagher N; Latham D; Nichols E; Prowant B
    ANNA J; 1989 Aug; 16(5):341-51. PubMed ID: 2673076
    [No Abstract]   [Full Text] [Related]  

  • 52. Epoetin alfa: focus on maintaining a higher, stable, Hct. Case study of the anemic patient.
    Cohen JA; Brattich M
    ANNA J; 1997 Oct; 24(5):574-80; quiz 581. PubMed ID: 9392740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health care outcomes case study: anemia in end-stage renal disease.
    Turco TF
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S19-23. PubMed ID: 8846242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial.
    Keown PA; Churchill DN; Poulin-Costello M; Lei L; Gantotti S; Agodoa I; Gitlin M; Gandra SR; Mayne TJ
    Hemodial Int; 2010 Apr; 14(2):168-73. PubMed ID: 20345390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transfusion therapy: associated risks and alternative approaches.
    Picard VT; Sayers MH; Spinowitz BS; Richner RE
    ANNA J; 1990 Dec; 17(6):457-64. PubMed ID: 2256728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perspectives on the improvement of quality of life with epoetin alfa therapy.
    Lundin AP; Delano BG; Quinn-Cefaro R
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):22S-26S. PubMed ID: 2345708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing.
    Keen ML
    ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
    Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
    Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of EPOGEN for treatment of anemia associated with chronic renal failure.
    Erlich L
    Crit Care Nurs Clin North Am; 1990 Mar; 2(1):101-13. PubMed ID: 2357306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.